Frontier Diagnostics

Who are Frontier Diagnostics

Led by industry-renowned biochemist Dr. Martin Burow (former Head of Asia Pacific at Thermo Fisher), we're not just developing new ways to detect cancer, we're changing the entire approach to how it's monitored, treated, and beaten.

Frontier Diagnostics are improving the survival rates of cancer patients and increasing their quality of life by using new revolutionary early detection techniques, Ai-driven tools, genomic insights, and precision medicine.

Frontier Diagnostics is developing a blood-based cancer diagnostic platform that enables clinicians to detect, understand, and monitor tumour behaviour using circulating tumour cells (CTCs). Suitable Investors can invest with exciting returns, and help the future of cancer care.

The Opportunity:

✔ Discounted Share Offer - £1.70 Price per share offer. £25.5m Valuation 

✔ ISO 15189 - accredited laboratory already operational

✔ Company forecasting - £61.75m revenue and £31.5m EBITDA by 2029

✔ Distribution partnerships across Europe and Southeast Asia

✔ Dual revenue model combining diagnostics testing with recurring hardware and consumables. 

✔ Minimum investment £12,000

EIS Benefits For Qualifying Investors Include

Investing through the Enterprise Investment Scheme (EIS) offers a range of government-backed tax incentives.

✔ 30% Income Tax Relief on investments of up to £1 million per tax year (or up to £2 million where at least £1 million is invested into knowledge-intensive companies), subject to individual circumstances. 

✔ Capital Gains Tax Deferral, allowing capital gains from other assets to be deferred by reinvesting into qualifying EIS shares. 

✔ Capital Gains Tax-Free Growth, provided the shares are held for a minimum of three years and all EIS conditions continue to be met. 

✔ Loss Relief, which may reduce the effective downside risk if the investment does not perform as expected, subject to your personal tax position. 

✔ Inheritance Tax Relief, with qualifying investments generally becoming eligible for 100% Business Relief after two years, provided the relevant conditions are met.

Any person accessing the email or profile and considering potential investment opportunities featured on the email should make their own commercial assessment of an investment opportunity after seeking the advice of an appropriately authorised or regulated financial advisor. This email should not be construed as advice or a personal recommendation to any prospective investor.